Delving into the Latest Updates on [18-F]CETO with Synapse

Overview

Basic Info

Drug Type

Chemical drugs, Diagnostic radiopharmaceuticals

Synonyms-

Target-

Mechanism

PET imaging(Positron-emission tomography enhancers)

Therapeutic Areas

Endocrinology and Metabolic Disease

Active Indication

Hyperaldosteronism

Inactive Indication

Acth-Independent Macronodular Adrenal HyperplasiaAdrenocortical AdenomaAdrenocortical Carcinoma

Originator Organization

University of Calgary

Active Organization

University of Calgary

Inactive Organization

University of Uppsala

University of Cambridge

Drug Highest PhasePhase 2

First Approval Date-

Regulation-

Login to view timeline

This study is to evaluate the accuracy of a novel radiopharmaceutical tracer, para-chloro-2-[18F]fluoroethyl etomidate (CETO), used with positron emission tomography (PET) and computed tomography (CT), as a way to subtype unilateral vs. bilateral forms of Primary Aldosteronism, compared to AVS as a reference gold standard.

Start Date01 Jan 2023

Sponsor / Collaborator

University of Calgary

NCT04529018 / Unknown statusNot Applicable

A Phase 1 Clinical Trial Evaluating the Safety and Efficacy of up to Two Administrations of the Adrenal PET Tracer [18F]CETO in Healthy Volunteers and Patients With Primary Aldosteronism

The study is a Phase 1, single-centre, open label, micro-dosing study. The aim is to investigate an innovative new tracer, [18F]CETO, as a potential alternative to adrenal vein sampling for the lateralisation of primary aldosteronism (PA).

Start Date03 Aug 2020

Sponsor / Collaborator

University of Cambridge

[+1]

NCT05361083 / CompletedEarly Phase 1

Studies of 18F-CETO as a Tracer for Adrenal PET Diagnostics

Purpose of this clinical phase 1 trial was to determine if para-chloro-2-[18F]fluoroethyletomidate positron emission computed tomography ([18F]CETO-positron emission computed tomography(PET)/computed tomography(CT)) can be used in diagnostics of adrenal tumors and if the biochemical/pharmacological states conditions in humans with various illnesses, compared to healthy humans, such as the radio tracer is suitable?

Start Date01 Sep 2019

Sponsor / Collaborator

University of Uppsala

[+1]

100 Clinical Results associated with [18-F]CETO

Login to view more data

100 Translational Medicine associated with [18-F]CETO

Login to view more data

100 Patents (Medical) associated with [18-F]CETO

Login to view more data

100 Deals associated with [18-F]CETO

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Hyperaldosteronism	Phase 2	CA	University of Calgary	01 Jan 2023
Acth-Independent Macronodular Adrenal Hyperplasia	Phase 1	SE	University of Uppsala	01 Sep 2019
Adrenocortical Adenoma	Phase 1	SE	University of Uppsala	01 Sep 2019
Adrenocortical Carcinoma	Phase 1	SE	University of Uppsala	01 Sep 2019